A Multi-national, Open-label, Dose Escalation Phase I/II study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types

Trial Profile

A Multi-national, Open-label, Dose Escalation Phase I/II study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs NKR 2 (Primary)
  • Indications Acute myeloid leukaemia; Bladder cancer; Breast cancer; Colorectal cancer; Haematological malignancies; Multiple myeloma; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms THINK
  • Sponsors Celyad
  • Most Recent Events

    • 19 Jun 2017 Early results at the 3-month follow-up of the first dose-level in the solid tumor arm of this trial published in a Celyad Media Release.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 19 May 2017 According to a Celyad media release, the company intends to recruit patients at three clinical centers, two of which have been initiated and approved (Roswell Park (NY) and University of Pittsburgh Medical Centre (PA)).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top